NCT04976153招募中3 期
Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study
Innovacell GmbH42 个研究点 分布在 12 个国家目标入组 290 人开始时间: 2022年5月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 290
- 试验地点
- 42
- 主要终点
- Changes in frequency of incontinence episodes
研究概览
简要总结
The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction caused by its disruption and/or weakness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be at least 18 years old
- •Patients who are mentally competent and able to understand all study requirements
- •Female patients of childbearing potential willing to use appropriate methods of contraception
- •Patient has symptoms of urge fecal incontinence with a disease duration of at least 6 months and did not improve sufficiently by conservative treatment performed for at least 3 months
- •Urge fecal incontinence episodes that occur more than twice a week
- •Maximal incremental voluntary squeeze pressure (increase to resting pressure) on anal manometry is 100mmHg or less in women and 150mmHg or less in men
- •9. Ultrasound of the anal canal showing intact external anal sphincter or a maximal overall extent of external anal sphincter injury and tear of 180 degrees
排除标准
- •Patients for whom the investigator determines that FI has a different cause than external anal sphincter dysfunction.
- •Patients with global fragmentation of the external anal sphincter as assessed by anal canal ultrasound
- •Patients who underwent any anorectal surgery within 6 months before screening visit
- •Patients who underwent a total of two or more external anal sphincter-related surgeries
- •Patients who currently have anal fistulas or fissures or have recurrent anal fistulas or fissures
- •Patients with poorly controlled chronic constipation including obstructed defecation syndrome
- •Patients with indications against a surgery under anesthesia
- •Patients with a malignant disease not in remission for 5 years or more
- •Patients who have undergone radiation therapy of the bowel and pelvis
- •Patients who have undergone chemotherapy within last 5 years prior to study enrolment and/or chemotherapy related neuropathy of the bowel and pelvis
- •Patients with compromised immune system and/or rheumatic disease, and patients under immunosuppressive therapy
- •Patients with a diagnosis of chronic inflammatory bowel disease (e.g Crohn's disease, Colitis Ulcerosa)
- •Patients suffering from a disease which has not been resolved within 4 weeks prior to screening including fever and/or diarrhea of unknown reasons (4 weeks)
- •Patients diagnosed with human immunodeficiency virus (HIV), acute or chronic viral hepatitis HCV, acute or chronic viral hepatitis HBV, active Syphilis or HTLV (tested upon risk assessment by investigator)
- •Patients diagnosed with any kind of skeletal muscle disease and/or neuronal disorders
- •Patients with severe myocardial disorders, irregular pulse or a pacemaker
- •Patients with implantations of metal components in the electrical stimulation treatment area
- •Patients with uncontrolled diabetes mellitus type I or II, or suffering from diabetic peripheral neuropathic pain
- •Patients with clinically relevant abnormal laboratory values judged by the responsible investigator as relevant for the study treatment
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo control is the vehicle solution used for the study product
干预措施: Placebo (Other)
aSMDC
Experimental
Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence
干预措施: aSMDC (Biological)
结局指标
主要结局
Changes in frequency of incontinence episodes
时间窗: 12 Months
Urge fecal incontinence
次要结局
未报告次要终点
研究者
研究点 (42)
Loading locations...
相似试验
已完成
不适用
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic AlopeciaAlopecia, AndrogeneticNCT02503852Kerastem Technologies, LLC71
已完成
1 期
Autologous Chondrocyte Transplantation For Articular Cartilage RegenerationKnee, Cartilage, Articular TearNCT01503970Instituto Nacional de Rehabilitacion10
终止
1 期
Autologous Cell Therapy for Ischemic Heart FailureIschemic Heart DiseaseNCT01353690Cook MyoSite9
已完成
1 期
Autologous Muscle Derived Stem Cells Transplantation in Urine IncontinencyStress IncontinencyNCT01963455Royan Institute10
已完成
1 期
Autologous Cell Therapy for Treatment of Fecal IncontinenceFecal IncontinenceNCT01600755Cook MyoSite53